Current and Emerging Options for Patients With Melanoma Brain Metastases

Abstract: Melanoma is the most aggressive skin cancer, with a high incidence of metastatic spread and a predilection for metastases to the brain. It represents the […]

How We Manage Idiopathic Multicentric Castleman Disease

Overview • We recommend first-line treatment with anti–interleukin 6 (anti–IL-6) for all patients with idiopathic multicentric Castleman disease. • We recommend enrollment of all patients with […]

A Narrative Review of Anti–SARS-CoV-2 Vaccines and Immune Thrombocytopenia: Be Aware, But Reassured

Abstract: Background: The COVID-19 pandemic gave rise to rapid development of anti–SARS-CoV-2 vaccines using established and new technologies. Immune thrombocytopenia (ITP) is a bleeding disorder that […]

Hematologic Concerns in Transgender Patients

Abstract: Patients with gender dysphoria are increasingly seeking gender-affirming therapies, which can have adverse hematologic effects. For example, estrogen can increase the risk for arterial and […]

New Treatment Strategies for Waldenström Macroglobulinemia

Abstract: The development of high-throughput technologies has allowed us to characterize the molecular landscape of hematologic neoplasms and identify somatic mutations. As a result, we can […]

JAK Inhibitors in the Treatment of Myelofibrosis

Abstract: Myelofibrosis (MF) is a myeloproliferative neoplasm driven by constitutive activation of the JAK/STAT pathway, resulting in clonal hematopoiesis, fibrotic replacement of the bone marrow, extramedullary […]

The Role of Circulating Tumor DNA in Evaluating Minimal Residual Disease in Luminal Gastrointestinal Malignancies

Abstract: The analysis of circulating tumor DNA (ctDNA) has multiple uses in oncology. In the past few years, studies with varying designs, methods, and quality have […]

Clonal Cytopenias of Undetermined Significance: Potential Predictor of Myeloid Malignancies?

Abstract: The recent identification of the potential for clonal replication in patients with unexplained cytopenias, resulting in myelodysplastic syndrome (MDS) or myeloid malignancies, has opened the […]

Follicular Lymphoma Grade 3: A Comprehensive Review

Abstract: Follicular lymphoma (FL) is a heterogeneous entity with disparate outcomes based on clinical and pathologic characteristics. An increasingly detailed understanding of high-grade FL (grade 3) […]

CAR T-Cell Therapy for Relapsed/Refractory Non-Hodgkin’s Lymphoma: A Comprehensive Review

Abstract: Non-Hodgkin lymphoma (NHL) is the seventh most common type of malignancy worldwide, with approximately 544,000 cases diagnosed in 2020.1-3 The vast majority of NHLs are […]

Systemic Management of Brain Metastases in HER2+ Breast Cancer in 2022

Abstract: Up to half of all patients with metastatic human epidermal growth factor receptor 2–positive (HER2+) breast cancer will eventually acquire brain metastases (BrMs), which are […]

Radiation Therapy and Immunotherapy in Locally Advanced NSCLC

H&O What is standard treatment in locally advanced non–small cell lung cancer (NSCLC)? PL Standard treatment in locally advanced NSCLC used to be 6 weeks of […]

Management of Acute Lymphoblastic Leukemia in Older Adults

Abstract: Acute lymphoblastic leukemia, commonly known to affect the younger population, is a disease that is affecting the elderly in an increasing amount as the human […]

The Treatment Landscape for Gastroesophageal Adenocarcinomas

Abstract: The treatment landscape for gastroesophageal adenocarcinomas has significantly changed over the last year. The addition of nivolumab to first-line chemotherapy has led to survival benefit […]

The Management of Psychological Issues in Oncology

Abstract: Psychological issues in the cancer setting are highly prevalent and well documented, and can lead to adverse outcomes. Several series of guidelines have been […]

CD19-Targeted CAR T Cells as Novel Cancer Immunotherapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Clinical Advances in Hematology & Oncology October 2016, Volume 14, Issue 10 Marco L. Davila, MD, PhD, and Renier J. Brentjens, MD, PhD Dr Davila is […]

The Role of High-Dose Melphalan and Autologous Stem Cell Transplant in the Rapidly Evolving Era of Modern Multiple Myeloma Therapy

Clinical Advances in Hematology & Oncology Volume 14, Issue 9, September 2016 Peter M. Voorhees, MD, and Saad Z. Usmani, MD The authors are affiliated with […]

Bruton’s Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia and Lymphoma

Clinical Advances in Hematology & Oncology Volume 14, Issue 7, July 2016 Gaurav Varma, MSPH, Tyler P. Johnson, MD, and Ranjana H. Advani, MD Mr Varma […]

Resistance Exercise Training in Patients With Genitourinary Cancers to Mitigate Treatment-Related Skeletal Muscle Loss

Clinical Advances in Hematology & Oncology Volume 14, Issue 6, June 2016 Oliver K. Glass, PhD, Sundhar Ramalingam, MD, and Michael R. Harrison, MD Dr Glass […]

Challenges of Conducting Clinical Trials of Natural Products to Combat Cancer

Clinical Advances in Hematology & Oncology Volume 14, Issue 6, June 2016 Channing J. Paller, MD, Samuel R. Denmeade, MD, and Michael A. Carducci, MD The […]